Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma

Ola Landgren, MD PhD, Melissa Alsina, MD, Noa Biran, MD, David H. Vesole, MD PhD, Paul K. Wallace, MS, PhD, Belle Fang, Gregory Arnold, Amy Kimball, MD PhD, David S. Siegel, MD PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-133803

Published: 2020

Journal Articles

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-140410

Published: 2020

Journal Articles

Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data

Shaji K. Kumar, MD, Al-Ola Abdallah, MD, Ashraf Z. Badros, MD, Betsy Laplant, MS, Binod Dhakal, MS, Melissa Alsina, MD, Rafat Abonour, MD, Cara A. Rosenbaum, MD, William I Bensinger, MD, Manisha Bhutani, MD, Andrzej Jakubowiak, MD PhD, Erica Kim, Brian G.M. Durie, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142584

Published: 2020

Journal Articles

Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s)

Jinming Song, MD PhD, Hailing Zhang, MD, Xiaohui Zhang, MD PhD, Mohammad Hussaini, MD, Ning Dong, MD, Lynn C Moscinski, Kenneth H. Shain, MD PhD, Melissa Alsina, MD, Taiga Nishihori, MD, Ling Zhang, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141656

Published: 2020

Journal Articles

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-142426

Published: 2020

Journal Articles

Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis

Ariel F Grajales-Cruz, MD, Cristian Ivan Rodriguez Arocho, MD, Ashley Rose, MD, Jamie Shapiro, PharmD, Elizabeth Finley-Oliver, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Taiga Nishihori, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Melissa Alsina, MD, Rachid Baz, MD

Blood (2019) 134 (Supplement_1): 3183.

https://doi.org/10.1182/blood-2019-129021

Published: 2019

Journal Articles

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Taiga Nishihori, MD, Rachid Baz, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Frederick L. Locke, MD, Jongphil Kim, PhD, Jinming Song, MD PhD, Michael Dumala, Melissa Alsina, MD

Blood (2019) 134 (Supplement_1): 3189.

https://doi.org/10.1182/blood-2019-131451

Published: 2019

Journal Articles

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, MD, Melissa Alsina, MD, Jose Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Jongphil Kim, PhD, Michael Dumala, Joel G. Turner, PhD, Daniel M Sullivan, MD

Blood (2019) 134 (Supplement_1): 3314.

https://doi.org/10.1182/blood-2019-131321

Published: 2019

Journal Articles

Reinforcement Learning to Optimize the Treatment of Multiple Myeloma

Kenneth H. Shain, MD PhD, Daniel Hart, Ariosto Siqueira Silva, PhD, Raghunandanreddy Alugubelli, MS, Gabriel De Avila, BS, Praneeth Reddy Sudalagunta, PhD, Alexandre Tungesvik, MD, Amit Kulkarni, PhD, Carmelo Blancuicett, PhD MD, Hongyue Dai, PhD, Taiga Nishihori, MD, Jason B. Brayer, PhDMD, Brandon Blue, MD, Melissa Alsina, MD, Rachid Baz, MD, William S. Dalton, PhDMD

Blood (2019) 134 (Supplement_1): 5511.

https://doi.org/10.1182/blood-2019-132234

Published: 2019

Journal Articles

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Mohammad O Hussaini, MD, Jaya Srivastava, PhD, Lik Wee Lee, PhD, Taiga Nishihori, MD, Bijal Shah, MD, Melissa Alsina, MD, Rachid Baz, MD, Javier Pinilla Ibarz, MD PhD, Kenneth H. Shain, MD PhD

Blood (2019) 134 (Supplement_1): 4654.

https://doi.org/10.1182/blood-2019-129846

Published: 2019

Journal Articles

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Melissa Alsina, MD, Nina D. Shah, MD, David S. Siegel, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L. Kaufman, MD, Nikhil C. Munshi, MD, Jacalyn Rosenblatt, MD, Jagoda K. Jasielec, MD, Yi Lin, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Monica Massaro, MPH, Timothy B. Campbell, MD PhD, Kristen Hege, Fabio Petrocca, MD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 927.

https://doi.org/10.1182/blood-2019-126660

Published: 2019

Journal Articles

Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival

AGM Mostofa, PhD, Allison Distler, Mark B. Meads, PhD, Eva Sahakian, PhD, John J. Powers, BS, Tuan Nguyen, Melissa Alsina, MD, Taiga Nishihori, MD, Rachid Baz, MD, Javier Pinilla Ibarz, MD, Eduardo Sotomayor, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhD MD

Blood (2018) 132 (Supplement 1): 3223.

https://doi.org/10.1182/blood-2018-99-119119

Published: 2018

Journal Articles

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

Nina Shah, MD, Melissa Alsina, MD, David S Siegel, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L Kaufman, MD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Monica Massaro, MPH, Kristen Hege, MD, Fabio Petrocca, MD, Jesus G. Berdeja, MD, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 488.

https://doi.org/10.1182/blood-2018-99-116953

Published: 2018

Journal Articles

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Rachid Baz, MD, Jeffrey A Zonder, MD, Kenneth H Shain, MD PhD, Melissa Alsina, MD, Jason B. Brayer, PhDMD, Mark Melody, Joel G. Turner, PhD, Jana L Dawson, Jongphil Kim, Daniel M Sullivan, MD

Blood (2017) 130 (Supplement 1): 3095.

https://doi.org/10.1182/blood.V130.Suppl_1.3095.3095

Published: 2017

Journal Articles

HDAC11 Is a Candidate Therapeutic Target in Multiple Myeloma

Jason B. Brayer, PhDMD, Allison Distler, Mark B. Meads, PhD, Eva Sahakian, PhD, John J. Powers, BS, Tuan Nguyen, Melissa Alsina, MD, Taiga Nishihori, MD, Rachid Baz, MD, Javier Pinilla-Ibarz, MD PhD, Eduardo Martin Sotomayor, MD, Ken H Shain, MD PhD

Blood (2017) 130 (Supplement 1): 1800.

https://doi.org/10.1182/blood.V130.Suppl_1.1800.1800

Published: 2017

Journal Articles

Updated Outcomes of Fludarabine/Melphalan/Bortezomib (Flu/Mel/Vel) Conditioning for Upfront Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma

Taiga Nishihori, MD, Claudio Anasetti, MD, Rachid Baz, MD, Jose L Ochoa-Bayona, MD, Kenneth H. Shain, MD PhD, Ryan Hillgruber, Melissa Alsina, MD

Blood (2016) 128 (22): 5885.

https://doi.org/10.1182/blood.V128.22.5885.5885

Published: 2016

Journal Articles

Promising Prognostic Values of Sequential Gene Expression Profiling in Multiple Myeloma Patients Undergoing Various Systemic Therapy

Yazan Migdady, MD MSc, Taiga Nishihori, MD, Rachid Baz, MD, Ram Thapa, PhD, Youngchul Kim, PhD, Dung-Tsa Chen, PhD, Ryan K Van Laar, PhD, Richard A Bender, MD, Siegel M Erin, PhD MPH, Vonetta Williams, PhD MPH, CTR, Michelle Fouriner, Melissa Alsina, MD, Kenneth H. Shain, MD PhD

Blood (2016) 128 (22): 5648.

https://doi.org/10.1182/blood.V128.22.5648.5648

Published: 2016

Journal Articles

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Shaji Kumar, MD, Meletios A Dimopoulos, Efstathios Kastritis, MD, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, MD, Jens Hillengass, MD, Xavier Leleu, Meral Beksac, MD, Melissa Alsina, MD, Albert Oriol, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Maria Victoria Mateos, Elizabeth K. O'Donnell, MD, Ravi Vij, MD MBA, Henk M. Lokhorst, MD PhD, Niels W.C.J. van de Donk, MD PhD, Chang-Ki Min, Tomer Mark, MD MSc, Ingemar Turesson, MD, PhD, Markus Hansson, MD, Heinz Ludwig, Sundar Jagannath, MD, Michel Delforge, MD PhD, Charalampia Kyriakou, MD PhD, Parameswaran Hari, MBBS, MD MRCP, Ulf-Henrik Mellqvist, MD PhD, Saad Z Usmani, MD FACP, Dominik Dytfeld, MD PhD, Ashraf Z Badros, MD, Philippe Moreau, Kihyun Kim, MD PhD, Paula Rodriguez Otero, MD, Jae Hoon Lee, MD, Chaim Shustik, MD, Daniel Waller, PhD, Wee Joo Chng, MD PhD, Shuji Ozaki, MD PhD, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, MD PhD, Laura Rosinol, MD PhD, Juan José Lahuerta, MD PhD, Anna Sureda, MD PhD, Jin Seok Kim, MD PhD, Brian G.M. Durie, MD

Blood (2016) 128 (22): 4414.

https://doi.org/10.1182/blood.V128.22.4414.4414

Published: 2016

Journal Articles

Validation of the Prognostic Significance of Gene Expression Profiling (GEP) Analysis on Myeloma Irrespective of Disease Status or Stage - a Single Center Academic Center Experience -

Taiga Nishihori, MD, Rachid Baz, MD, Ram Thapa, PhD, Youngchul Kim, PhD, Dung-Tsa Chen, PhD, Yazan Migdady, MD, Ryan K Van Laar, PhD, Richard A Bender, MD, Erin M Siegel, PhD MPH, Vonetta Williams, PhD MPH, CTR, Michelle Fournier, Melissa Alsina, MD, Kenneth H. Shain, MD PhD

Blood (2016) 128 (22): 4417.

https://doi.org/10.1182/blood.V128.22.4417.4417

Published: 2016

Journal Articles

Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study

Blood (2015) 126 (23): 4201.

https://doi.org/10.1182/blood.V126.23.4201.4201

Published: 2015

NARROW

Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data

Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s)

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Reinforcement Learning to Optimize the Treatment of Multiple Myeloma

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

HDAC11 Is a Candidate Therapeutic Target in Multiple Myeloma

Updated Outcomes of Fludarabine/Melphalan/Bortezomib (Flu/Mel/Vel) Conditioning for Upfront Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma

Promising Prognostic Values of Sequential Gene Expression Profiling in Multiple Myeloma Patients Undergoing Various Systemic Therapy

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Validation of the Prognostic Significance of Gene Expression Profiling (GEP) Analysis on Myeloma Irrespective of Disease Status or Stage - a Single Center Academic Center Experience -

Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only